Anosognosia in amyotrophic lateral sclerosis: A cross-sectional study of 85 individuals and their relatives.


Journal

Annals of physical and rehabilitation medicine
ISSN: 1877-0665
Titre abrégé: Ann Phys Rehabil Med
Pays: Netherlands
ID NLM: 101502773

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 12 03 2020
revised: 09 08 2020
accepted: 26 08 2020
pubmed: 17 10 2020
medline: 26 11 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

Amyotrophic lateral sclerosis (ALS) has long been considered a pure motor neurodegenerative disease. However, now, extra-motor manifestations such as cognitive-behavioral disorders are considered not rare and are even a severity factor of the disease. Experiencing anosognosia (i.e., the inability to recognize neurological symptoms) might affect care and treatment compliance in ALS. Regardless, this pivotal feature has been little investigated. By comparing patients' and caregivers' reports, we analysed whether patients with ALS would experience a lack of awareness about their executive disorders and their apathy symptoms. From the ALS reference center in Paris, we included 85 patients (47 men, mean [SD] age 60.5 [12] years and ALS-Functional Rating Scale-revised score 8 to 46) and their primary family caregivers who all completed the Dysexecutive Questionnaire (DEX) and the Apathy Evaluation Scale (AES). Overall scores and answers were compared by agreement/disagreement statistical methods. Caregivers reported higher levels of cognitive-behavioral disorders than did patients, but reports matched when cognitive-behavioral disorders were absent or mild. With published DEX and AES cutoffs, 32% and 51% of patients had executive disorders and apathy, respectively. In these patients with significant impairment, Bland-Altman plots (i.e., visual display agreement that represents the difference between the patient's and caregiver's scores as a function of their average) showed a strong discrepancy between joint reports: patients underestimated their symptoms by a mean bias of -6.81 DEX points (95% confidence interval -11.88, -1.75) and -8.85 AES points (95% confidence interval -11.72, -5.98). We found no clear relationship between bulbar or spinal ALS subtypes and anosognosia. ALS patients with a cognitive-behavioral phenotype show anosognosia by a mismatch between self and proxy reports, which warrants further investigation in neuroimaging. Systematic longitudinal screening of anosognosia is needed to propose targeted psychoeducation in patient-caregiver dyads showing disagreement.

Sections du résumé

BACKGROUND BACKGROUND
Amyotrophic lateral sclerosis (ALS) has long been considered a pure motor neurodegenerative disease. However, now, extra-motor manifestations such as cognitive-behavioral disorders are considered not rare and are even a severity factor of the disease. Experiencing anosognosia (i.e., the inability to recognize neurological symptoms) might affect care and treatment compliance in ALS. Regardless, this pivotal feature has been little investigated.
OBJECTIVES OBJECTIVE
By comparing patients' and caregivers' reports, we analysed whether patients with ALS would experience a lack of awareness about their executive disorders and their apathy symptoms.
METHODS METHODS
From the ALS reference center in Paris, we included 85 patients (47 men, mean [SD] age 60.5 [12] years and ALS-Functional Rating Scale-revised score 8 to 46) and their primary family caregivers who all completed the Dysexecutive Questionnaire (DEX) and the Apathy Evaluation Scale (AES). Overall scores and answers were compared by agreement/disagreement statistical methods.
RESULTS RESULTS
Caregivers reported higher levels of cognitive-behavioral disorders than did patients, but reports matched when cognitive-behavioral disorders were absent or mild. With published DEX and AES cutoffs, 32% and 51% of patients had executive disorders and apathy, respectively. In these patients with significant impairment, Bland-Altman plots (i.e., visual display agreement that represents the difference between the patient's and caregiver's scores as a function of their average) showed a strong discrepancy between joint reports: patients underestimated their symptoms by a mean bias of -6.81 DEX points (95% confidence interval -11.88, -1.75) and -8.85 AES points (95% confidence interval -11.72, -5.98). We found no clear relationship between bulbar or spinal ALS subtypes and anosognosia.
CONCLUSIONS CONCLUSIONS
ALS patients with a cognitive-behavioral phenotype show anosognosia by a mismatch between self and proxy reports, which warrants further investigation in neuroimaging. Systematic longitudinal screening of anosognosia is needed to propose targeted psychoeducation in patient-caregiver dyads showing disagreement.

Identifiants

pubmed: 33065300
pii: S1877-0657(20)30171-8
doi: 10.1016/j.rehab.2020.08.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101440

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Amina Ben Salah (AB)

Department of Physical Rehabilitation Medicine, Pitié-Salpêtrière hospital (AP-HP) and GRC 24 (Sorbonne Université), 47, boulevard de l'Hôpital, 75013 Paris, France.

Pierre-François Pradat (PF)

Laboratoire d'imagerie biomédicale (LIB), Sorbonne université, Paris, France; Department of Neurology and Reference ALS Center, Pitié-Salpêtrière Hospital (AP-HP), Paris, France.

Marie Villain (M)

Department of Physical Rehabilitation Medicine, Pitié-Salpêtrière hospital (AP-HP) and GRC 24 (Sorbonne Université), 47, boulevard de l'Hôpital, 75013 Paris, France.

Alexander Balcerac (A)

Department of Physical Rehabilitation Medicine, Pitié-Salpêtrière hospital (AP-HP) and GRC 24 (Sorbonne Université), 47, boulevard de l'Hôpital, 75013 Paris, France.

Pascale Pradat-Diehl (P)

Department of Physical Rehabilitation Medicine, Pitié-Salpêtrière hospital (AP-HP) and GRC 24 (Sorbonne Université), 47, boulevard de l'Hôpital, 75013 Paris, France; Laboratoire d'imagerie biomédicale (LIB), Sorbonne université, Paris, France.

Francois Salachas (F)

Department of Neurology and Reference ALS Center, Pitié-Salpêtrière Hospital (AP-HP), Paris, France.

Lucette Lacomblez (L)

Department of Neurology and Reference ALS Center, Pitié-Salpêtrière Hospital (AP-HP), Paris, France.

Eléonore Bayen (E)

Department of Physical Rehabilitation Medicine, Pitié-Salpêtrière hospital (AP-HP) and GRC 24 (Sorbonne Université), 47, boulevard de l'Hôpital, 75013 Paris, France; Laboratoire d'imagerie biomédicale (LIB), Sorbonne université, Paris, France; Global Brain Health Institute, Memory and Aging Center, University of California San Francisco, San Francisco, USA. Electronic address: Eleonore.bayen@gbhi.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH